Lexaria Bioscience Corp. (LEXX) intrinsic value & 10-year financials
Lexaria Bioscience Corp. (LEXX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 37.3% a year to $705.9K, with an average return on invested capital of -342.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.86
- Market cap
- $51.5M
- Revenue (FY2025)
- $705.9K
- Revenue growth (10-yr CAGR)
- 37.3%
- ROIC (10-yr avg)
- -342.9%
- Free cash flow (FY2025)
- -$10.5M
LEXX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $705.9K | -$11.9M | -$0.66 | -$10.5M | -1683.0% | -787.8% |
| FY2024 | $464.3K | -$5.8M | -$0.47 | -$5.0M | -1239.2% | -323.5% |
| FY2023 | $226.2K | -$6.7M | -$1.01 | -$5.9M | -2888.5% | -335.7% |
| FY2022 | $255.4K | -$7.3M | — | -$4.9M | -2891.0% | -336.5% |
| FY2021 | $722.7K | -$4.2M | — | — | -786.8% | -318.9% |
| FY2020 | $384.5K | -$4.1M | — | -$2.7M | — | -309.2% |
| FY2019 | $222.6K | -$4.2M | — | -$3.7M | — | -174.3% |
| FY2018 | $433.3K | -$6.6M | — | — | — | -245.0% |
| FY2017 | $63.6K | -$1.9M | — | -$1.5M | — | -117.9% |
| FY2016 | $40.7K | -$1.3M | — | -$664.0K | -3136.8% | -480.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Lexaria Bioscience Corp. is a consistent compounder, expanding top-line revenue at 37.3% annually over the past decade.
Lexaria Bioscience Corp. has historically struggled to out-earn its cost of capital, averaging just -15.1% ROIC.
Lexaria Bioscience Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Lexaria Bioscience Corp. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-21.92 per share.